Hematological Malignancy
Showing NaN - NaN of 4
Hematological Malignancy Trial in Houston (Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells)
Not yet recruiting
- Hematological Malignancy
- Fludarabine Phosphate
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Following Treatment With Fate Therapeutics' Engineered Cellular
Terminated
- Hematological Malignancy
- Genetically engineered NK cells
-
Phoenix, Arizona
- +4 more
Aug 24, 2022
Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia Trial in Worldwide (MT-3724
Terminated
- Non-Hodgkin's B-cell Lymphoma
- +5 more
- MT-3724 Phase 1
- MT-3724 Phase 2
-
Tucson, Arizona
- +40 more
Jul 18, 2022
Hematological Malignancy Trial in United States (isavuconazonium sulfate - intravenous, isavuconazonium sulfate - oral)
Completed
- Hematological Malignancy
- isavuconazonium sulfate - intravenous
- isavuconazonium sulfate - oral
-
Long Beach, California
- +15 more
Jun 30, 2020